Lineage Cell Therapeutics Inc (LCTX) support and resistance · rev $9.5M
Lineage Cell Therapeutics Inc (LCTX) is a biotechnology company listed on US.
This page maps Lineage Cell Therapeutics Inc (LCTX) support and resistance from cached range and valuation — not a live tape and not a trade alert.
Latest reported LCTX revenue for 2024-12-31 was $9.5M. Net income was -$18.6M. Revenue was up 354.9% from 2023-12-31 to 2024-12-31. LCTX currently screens at market cap $213.6M.
LCTX currently screens at market cap $213.6M. Round numbers near that cap and multiple often act as psychological resistance; prior-period revenue is the fundamental floor traders argue about.
A new LCTX 8-K or 10-Q can move the levels that matter more than a drawing on a chart.
Not investment advice. Use the LCTX quote page for the session range and the stock page for the full model.
Not investment advice.